| Boca Raton Neurologic Associates Pa | |
|
1050 Nw 15th St Suite 216-a Boca Raton FL 33486-1375 | |
| (561) 338-8484 | |
| (561) 338-8492 |
| Full Name | Boca Raton Neurologic Associates Pa |
|---|---|
| Speciality | Psychiatry & Neurology |
| Location | 1050 Nw 15th St, Boca Raton, Florida |
| Authorized Official Name and Position | Bruce R Kastin (OWNER) |
| Authorized Official Contact | 5613388484 |
| Accepts Medicare Insurance | Yes. This clinic participates in medicare program and accept medicare insurance. |
| Mailing Address | Practice Location Address |
|---|---|
| Boca Raton Neurologic Associates Pa 1050 Nw 15th St Suite 216-a Boca Raton FL 33486-1375 Ph: (561) 338-8484 | Boca Raton Neurologic Associates Pa 1050 Nw 15th St Suite 216-a Boca Raton FL 33486-1375 Ph: (561) 338-8484 |
| NPI Number | 1083676035 |
|---|---|
| Provider Enumeration Date | 04/05/2006 |
| Last Update Date | 06/12/2008 |
| Medicare PECOS PAC ID | 4981737145 |
|---|---|
| Medicare Enrollment ID | O20100809000833 |
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1083676035 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2084N0400X | Psychiatry & Neurology - Neurology | ME 66113 (Florida) | Primary |
| Provider Name | Annet Ella Falchook |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1770658882 PECOS PAC ID: 2860524972 Enrollment ID: I20100723000959 |
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
| Provider Name | Lorin Michael Graef |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1750343703 PECOS PAC ID: 8123151396 Enrollment ID: I20100902000631 |
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
| Provider Name | Adam D Falchook |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1780773465 PECOS PAC ID: 8426226408 Enrollment ID: I20110718000567 |
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
| Provider Name | Douglas J Black |
|---|---|
| Provider Type | Practitioner - Neurology |
| Provider Identifiers | NPI Number: 1598753832 PECOS PAC ID: 3274677075 Enrollment ID: I20210326000644 |
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
News Archive
Hotspots in two areas of a gene that encodes a specific signaling enzyme, or kinase, are vulnerable to a variety of mutations found in five types of brain cancers, according to a report published in the August 1 issue of the journal Cancer Research.
Onyx Pharmaceuticals, Inc. today announced that the company has completed its acquisition of Proteolix, Inc., a privately held biopharmaceutical company focused on discovering and developing novel therapies that target the proteasome for the treatment of hematological malignancies and solid tumors.
The Massachusetts Eye and Ear Infirmary, Harvard Medical School Department of Ophthalmology, has been awarded a grant renewal from the National Institutes of Health, National Eye Institute (NEI), to recruit, train and support first-rate clinician scientists to promote translational and clinical research into cures for eye disease.
Oligomerix, Inc., a privately held company pioneering the development of tau oligomer inhibitors for Alzheimer's disease and related neurodegenerative disorders, and the Feinstein Institutes for Medical Research announced today the publication of preclinical data demonstrating that an oral small molecule drug inhibits the formation of neurotoxic tau oligomers in an animal model of tau aggregation most relevant to AD.
Amnis Corporation, a manufacturer of advanced cell imaging systems, today announced the first commercial shipments of the new ImageStreamX imaging flow cytometers. The new instrument - the second generation of Amnis' patented ImageStream® technology - combines the speed, sensitivity, and phenotyping abilities of flow cytometry with the detailed imagery, rich feature set, and functional insights of microscopy.
› Verified 3 days ago
Meryl B. Rome, Md, Pa Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7100 W Camino Real, Ste. 207, Boca Raton, FL 33433 Phone: 561-391-2770 Fax: 561-391-2930 | |
Kegley Counseling, Llc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 3200 N Federal Hwy Ste 206-7, Boca Raton, FL 33431 Phone: 404-496-8849 Fax: 404-591-7909 | |
Lifetime Health Services Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 433 Plaza Real Ste 275, Boca Raton, FL 33432 Phone: 786-226-5377 | |
Creative Minds Aba Services Inc Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 1700 N Dixie Hwy Ste 122, Boca Raton, FL 33432 Phone: 305-305-3181 | |
Ronald L Seifer Ph D Pa Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 7300 W Camino Real, Suite 230, Boca Raton, FL 33433 Phone: 561-699-7455 Fax: 954-340-3407 | |
James Cocores Md Pa Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 5301 N Federal Hwy, Suite 270, Boca Raton, FL 33487 Phone: 561-989-9393 Fax: 561-989-9369 | |
L. Dennison Reed, Psy.d., P.a. Mental Health Clinic Medicare: Not Enrolled in Medicare Practice Location: 4710 Nw Boca Raton Blvd, Suite 104, Boca Raton, FL 33431 Phone: 954-427-8883 Fax: 954-427-3813 |